Beck, O.; Paret, C.; Russo, A.; Burhenne, J.; Fresnais, M.; Steimel, K.; Seidmann, L.; Wagner, D.-C.; Vewinger, N.; Lehmann, N.;
et al. Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. Cancers 2020, 12, 793.
https://doi.org/10.3390/cancers12040793
AMA Style
Beck O, Paret C, Russo A, Burhenne J, Fresnais M, Steimel K, Seidmann L, Wagner D-C, Vewinger N, Lehmann N,
et al. Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. Cancers. 2020; 12(4):793.
https://doi.org/10.3390/cancers12040793
Chicago/Turabian Style
Beck, Olaf, Claudia Paret, Alexandra Russo, Jürgen Burhenne, Margaux Fresnais, Kevin Steimel, Larissa Seidmann, Daniel-Christoph Wagner, Nadine Vewinger, Nadine Lehmann,
and et al. 2020. "Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma" Cancers 12, no. 4: 793.
https://doi.org/10.3390/cancers12040793
APA Style
Beck, O., Paret, C., Russo, A., Burhenne, J., Fresnais, M., Steimel, K., Seidmann, L., Wagner, D.-C., Vewinger, N., Lehmann, N., Sprang, M., Backes, N., Roth, L., Neu, M. A., Wingerter, A., Henninger, N., El Malki, K., Otto, H., Alt, F.,
... Faber, J.
(2020). Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. Cancers, 12(4), 793.
https://doi.org/10.3390/cancers12040793